Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.

[1]  D. Paty,et al.  TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study , 1999, Neurology.

[2]  S. Suissa,et al.  Demyelinating events in rheumatoid arthritis after drug exposures , 2009, Annals of the rheumatic diseases.

[3]  Marco Rovaris,et al.  A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. , 2009, Archives of neurology.

[4]  L. Carmona,et al.  Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort , 2008, Arthritis research & therapy.

[5]  J. W. Pendleton,et al.  Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. , 2008, The Journal of rheumatology.

[6]  J. Grigg,et al.  Ophthalmic manifestations of demyelination secondary to etanercept , 2008, Clinical & experimental ophthalmology.

[7]  T. Ishida,et al.  A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy , 2008, Modern rheumatology.

[8]  J. Swarowska-Knap,et al.  Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[9]  C. Pfueller,et al.  Multiple sclerosis following etanercept treatment for ankylosing spondylitis , 2008, Scandinavian journal of rheumatology.

[10]  S. Silburn,et al.  Guillain–Barré syndrome in a patient receiving anti-tumour necrosis factor α for rheumatoid arthritis: a case report and discussion of literature , 2007, Annals of the rheumatic diseases.

[11]  J. Meca-Lallana,et al.  Multiple Sclerosis Onset during Etanercept Treatment , 2007, European Neurology.

[12]  L. Gordon,et al.  Etanercept associated optic neuropathy , 2007, Clinical & experimental ophthalmology.

[13]  H. Erdem,et al.  Optic neuritis occurring with anti-tumour necrosis factor α therapy , 2007 .

[14]  J. Mendicute,et al.  [Retrobulbar optic neuritis associated with Infliximab]. , 2007, Archivos de la Sociedad Espanola de Oftalmologia.

[15]  H. Erdem,et al.  Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. , 2007, Annals of the rheumatic diseases.

[16]  J. Valat,et al.  Adalimumab-associated multiple sclerosis. , 2007, The Journal of rheumatology.

[17]  Adeel Nasir,et al.  TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries. , 2007, Bulletin of the NYU hospital for joint diseases.

[18]  I. Sezer,et al.  Adverse effect of TNF‐alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report , 2006, Journal of clinical pharmacy and therapeutics.

[19]  M. Tektonidou,et al.  Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment , 2006, Clinical Rheumatology.

[20]  A. Carvajal,et al.  Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. , 2006, The Journal of rheumatology.

[21]  Nawar Al Saieg,et al.  Etanercept induced multiple sclerosis and transverse myelitis. , 2006, The Journal of rheumatology.

[22]  R. Turbin,et al.  Adalimumab-associated optic neuritis , 2006, Journal of the Neurological Sciences.

[23]  X. Mariette,et al.  Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance. , 2006, The Journal of rheumatology.

[24]  D. Zochodne,et al.  Neurological complications of infliximab. , 2006, Journal of Rheumatology.

[25]  E. Papadopoulos,et al.  Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. , 2006, Arthritis and rheumatism.

[26]  V. Brinar,et al.  CNS demyelination in autoimmune diseases , 2006, Clinical Neurology and Neurosurgery.

[27]  M. Garcerá,et al.  Vitellogenin polypeptide levels in one susceptible and one cadmium-resistant strain of Oncopeltus fasciatus (Heteroptera: Lygaeidae), and its role in cadmium resistance. , 2006, Journal of insect physiology.

[28]  I. Avni,et al.  Optic neuritis associated with etanercept therapy for juvenile arthritis. , 2006, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[29]  J. Val-Bernal,et al.  Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis , 2006, Scandinavian journal of rheumatology.

[30]  Shunsuke Kobayashi,et al.  New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients , 2006, Clinical Rheumatology.

[31]  L. Provinciali,et al.  CNS demyelination during anti–tumor necrosis factor alpha therapy , 2006, Journal of Neurology.

[32]  J. Borrás-Blasco,et al.  Optic Neuritis with Concurrent Etanercept and Isoniazid Therapy , 2005, The Annals of pharmacotherapy.

[33]  B. Bergamasco,et al.  Multifocal motor neuropathy during treatment with infliximab , 2005, Journal of the peripheral nervous system : JPNS.

[34]  J. Maymó-Guarch,et al.  Esclerosis múltiple tras tratamiento con anticuerpo anti-TNF-α , 2005 .

[35]  M. Arias,et al.  [Brachial plexitis and myelitis and herpes-zoster lumbar plexus disorder in patient treated with infliximab]. , 2005, Neurologia.

[36]  J. Gómez-Reino,et al.  Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. , 2005, Arthritis and rheumatism.

[37]  R. Kinkel,et al.  Anti-tumor necrosis factor alpha-associated multiple sclerosis. , 2005, AJNR. American journal of neuroradiology.

[38]  P. Blanco,et al.  Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers , 2005, Neurology.

[39]  K. Papadakis,et al.  Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. , 2005, Journal of clinical gastroenterology.

[40]  M. Warmuth-Metz,et al.  Cerebral demyelination in association with TNF‐inhibition therapy in a 5‐year‐old girl with aseptic meningitis as the first symptom of Still's disease , 2005, Scandinavian journal of rheumatology.

[41]  J. Belzunegui,et al.  Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. , 2005, Rheumatology.

[42]  H. Freeman,et al.  Demyelination-like syndrome in Crohn's disease after infliximab therapy. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[43]  G. Rosati,et al.  Genes, environment, and susceptibility to multiple sclerosis , 2004, Neurobiology of Disease.

[44]  P. Dieudé,et al.  Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. , 2004, The Journal of rheumatology.

[45]  E. Brown,et al.  Using MedDRA , 2004, Drug safety.

[46]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[47]  M. Ten Tusscher,et al.  Bilateral anterior toxic optic neuropathy and the use of infliximab , 2003, BMJ : British Medical Journal.

[48]  S. Jacobelli,et al.  Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. , 2002, Arthritis and rheumatism.

[49]  M. Hernández.  Epidemiology of multiple sclerosis in the Canary Islands (Spain) , 2002, Journal of Neurology.

[50]  L. Carmona,et al.  The prevalence of rheumatoid arthritis in the general population of Spain. , 2002, Rheumatology.

[51]  M. Hernández.  Epidemiology of multiple sclerosis in the Canary Islands (Spain): a study on the island of La Palma. , 2002, Journal of neurology.

[52]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[53]  N. Sicotte,et al.  Onset of multiple sclerosis associated with anti-TNF therapy , 2001, Neurology.

[54]  W. Robinson,et al.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? , 2001, Arthritis and rheumatism.

[55]  X. Montalban,et al.  Frequency of Multiple Sclerosis in Menorca, Balearic Islands, Spain , 2001, Neuroepidemiology.

[56]  F. Barkhof,et al.  Decreased interleukin‐10 and increased interleukin‐12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis , 1999, Annals of neurology.

[57]  D. Wendling,et al.  Rheumatoid arthritis and multiple sclerosis in the same patient. Two case-reports. , 1999, Revue du rhumatisme.

[58]  J. Benito-León,et al.  Multiple sclerosis in Móstoles, central Spain , 1998, Acta neurologica Scandinavica.

[59]  P. Modrego,et al.  Prevalence of multiple sclerosis in the province of Teruel, Spain , 1997, Journal of Neurology.

[60]  F. Barkhof,et al.  Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.

[61]  T. Riise,et al.  Multiple sclerosis and chronic inflammatory diseases A case‐control study , 1996, Acta neurologica Scandinavica.

[62]  K. Selmaj,et al.  Experimental autoimmune encephalomyelitis , 1995, Neurology.

[63]  B. Scallon,et al.  Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins , 1994, European journal of immunology.

[64]  D. McFarlin,et al.  Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.

[65]  A. Cross,et al.  Anti—tumor necrosis factor therapy abrogates autoimmune demyelination , 1991, Annals of neurology.

[66]  M. Sharief,et al.  Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis , 1991 .

[67]  A. Reder,et al.  Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis , 1991, Journal of Neuroimmunology.

[68]  C. Brosnan,et al.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. , 1991, The Journal of clinical investigation.

[69]  J. Merrill,et al.  Tumor necrosis factor identified in multiple sclerosis brain , 1989, The Journal of experimental medicine.